MPN ASH 22

Leah SherwoodMeeting News | April 12, 2023
John Mascarenhas, MD, discusses the results of the PACIFICA trial at the 2022 American Society of Hematology Annual Meeting.
Leah SherwoodMeeting News | May 30, 2023
Whole blood mutation allele frequency had only weak prognostic value in certain patients with polycythemia vera.
Keightley AmenMyeloproliferative Neoplasms | December 12, 2022
Several factors were independently associated with arterial thrombotic events in patients with myeloproliferative neoplasms.
Advertisement
Keightley AmenMeeting News | December 10, 2022
Symptom-related quality of life is linked with the type of cytoreductive treatment used for MPNs.
Keightley AmenMyelofibrosis | April 12, 2023
TP53 and complex karyotype are very high-risk factors in patients with myelofibrosis undergoing HSCT.
Keightley AmenMyelofibrosis | April 12, 2023
The combination of ruxolitinib and pegylated IFNα2a showed significant reductions in spleen length.
Advertisement
Keightley AmenMeeting News | April 12, 2023
BMS-986158 combined with ruxolitinib or fedratinib reduced spleen volume in patients with myelofibrosis.
Kerri FitzgeraldMyelofibrosis | April 12, 2023
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
Kerri FitzgeraldMyeloproliferative Neoplasms | May 30, 2023
The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera.
Kerri FitzgeraldMyelofibrosis | April 12, 2023
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
Keightley AmenMeeting News | December 10, 2022
Long-term follow-up results of a phase II study of ruxolitinib in patients with MPNs were presented at the 2022 ASH Meeting.
Keightley AmenMyeloproliferative Neoplasms | May 30, 2023
New data support the use of ropeginterferon alfa-2b therapy in patients with low-risk or high-risk PV,
Keightley AmenMyeloproliferative Neoplasms | May 30, 2023
An analysis of patients with MF found that the combination of navitoclax and ruxolitinib reduced MF-associated splenomegaly.
Keightley AmenMyeloproliferative Neoplasms | May 30, 2023
IFNα2 treatment may help reduce the risk of arterial and venous thrombosis in patients with myeloproliferative neoplasms ...
Advertisement
Advertisement
Editorial Board